newsfilter
← Latest News
Business Wire·

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Q2 marked a critical inflection point in EB-003 development with mechanism confirmation, therapeutic opportunity expansion, IND-enabling progress, and continued strengthening of Enveric's differentiated neuroplastogen